Jinwu Financial News | Healthcare concepts are rising. As of press release, Lai Kai Pharmaceutical (02105) rose 10.02%, Pharmaceutical Kangde (02359) rose 9.80%, Pharmaceutical Biotech (02269) rose 9.47%, Cinda Biotech (01801) rose 8.79%, and Ali Health (00241) rose 7.26%.
The National Health Insurance Administration's “Notice on Establishing a Initial Price Formation Mechanism for Newly Launched Chemical Drugs to Encourage High Quality Innovation” solicited comments through relevant industry associations. Among them, protective measures such as “the higher the self-evaluation score, the higher the value content of drug innovation, the higher the degree of freedom in the initial price of newly launched drugs”, “the number of self-ratings is high and high, giving a stable initial price period of 1-5 years, not included in collection during the stabilization period, and in principle not interfering with online prices” are regarded by the industry as support for “true innovation.”
Furthermore, Yao Ming Kangde announced that the company implemented the repurchase of the company's shares for the first time through centralized bidding transactions, using a total capital of about 1 billion yuan; Tiger Pharmaceuticals also stated that it plans to repurchase some A shares, with a capital limit of 1 billion yuan; and Zhaoyan Pharmaceutical proposed to repurchase A shares at most 100 million yuan. According to reports, a number of pharmaceutical companies have recently repurchased shares. Listed companies such as Gloria Ying, Haixiang Pharmaceutical, Yiqiao Shenzhou, and Dian Diagnosis have repurchased or are planning to repurchase more than 100 million yuan.
Furthermore, the US biotechnology protection bill, which previously triggered a sharp drop in individual stocks such as Pharmaceuticals, has been adjourned in the Senate.